Financial giants have made a conspicuous bearish move on Teva Pharmaceutical Indus. Our analysis of options history for Teva Pharmaceutical Indus TEVA revealed 8 unusual trades.
Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $549,677, and 2 were calls, valued at $54,484.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $30.0 for Teva Pharmaceutical Indus during the past quarter.
Volume & Open Interest Trends
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Teva Pharmaceutical Indus’s options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teva Pharmaceutical Indus’s whale trades within a strike price range from $15.0 to $30.0 in the last 30 days.
Teva Pharmaceutical Indus Call and Put Volume: 30-Day Overview
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TEVA | PUT | TRADE | BULLISH | 03/28/25 | $16.05 | $14.3 | $14.47 | $30.00 | $144.7K | 0 | 185 |
| TEVA | PUT | SWEEP | BEARISH | 02/20/26 | $6.7 | $6.6 | $6.7 | $22.00 | $140.7K | 305 | 211 |
| TEVA | PUT | TRADE | BEARISH | 03/28/25 | $14.4 | $14.4 | $14.4 | $30.00 | $122.4K | 0 | 85 |
| TEVA | PUT | SWEEP | BEARISH | 02/20/26 | $5.0 | $4.95 | $5.0 | $20.00 | $86.5K | 326 | 174 |
| TEVA | PUT | TRADE | BULLISH | 03/28/25 | $0.38 | $0.32 | $0.33 | $16.00 | $29.7K | 713 | 932 |
About Teva Pharmaceutical Indus
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Teva Pharmaceutical Indus’s Current Market Status
- Trading volume stands at 4,251,835, with TEVA’s price down by -1.02%, positioned at $15.53.
- RSI indicators show the stock to be is currently neutral between overbought and oversold.
- Earnings announcement expected in 41 days.
What Analysts Are Saying About Teva Pharmaceutical Indus
1 market experts have recently issued ratings for this stock, with a consensus target price of $20.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
* An analyst from B of A Securities has decided to maintain their Buy rating on Teva Pharmaceutical Indus, which currently sits at a price target of $20.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Teva Pharmaceutical Indus, Benzinga Pro gives you real-time options trades alerts.
Momentum51.75
Growth7.73
Quality44.57
Value31.70
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
